Sugi Predict

Sugi Predict / Compounds / SCHEMBL7439787

SCHEMBL7439787

SCHEMBL7439787

CC(NC(=O)C(C)NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.50
▸ CTSK P43235 7/20 0.46
▸ CTSS P25774 6/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ GLS O94925 1/20 0.42
▸ CYP2D6 P10635 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ ATM Q13315 1/20 0.40
▸ MME P08473 1/20 0.40
▸ ACE P12821 1/20 0.40
▸ CPA1 P15085 1/20 0.40
▸ ACE2 Q9BYF1 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17664986 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL10607843 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL9980754 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL30471514 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL9980671 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL7057277 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL30471384 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL6891888 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL148100 0.92 CA1 (0.52) KMT2ACTSKCTSSCA1CA2
SCHEMBL148099 0.92 CA1 (0.52) KMT2ACTSKCTSSCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503452-B2 Antimicrobial compounds and methods CURZA GLOBAL, LLC (US) 2025-12-23 — — US disclosed
US-12478689-B2 Anti-CD19 antibody drug conjugates ABBVIE BIOTHERAPEUTICS INC. (US) 2025-11-25 — — US disclosed
EP-4631952-A1 GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-10-15 — — EP disclosed
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2025-10-02 — — US disclosed
EP-4608453-A1 EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Merck Sharp & Dohme LLC (US) 2025-09-03 — — EP disclosed
WO-2024235128-A9 ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-19 — — WO disclosed
WO-2024235132-A9 COMPOUND HAVING BIOLOGICAL ACTIVITY, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-19 — — WO disclosed
EP-4539888-A1 ANTI-CD19 ANTIBODY DRUG CONJUGATES ABBVIE BIOTHERAPEUTICS INC. (US) 2025-04-23 — — EP disclosed
US-20250064961-A1 ANTI-CD19 ANTIBODY DRUG CONJUGATES ABBVIE BIOTHERAPEUTICS INC. 2025-02-27 — — US disclosed
US-20250064962-A1 ANTI-CD19 ANTIBODY DRUG CONJUGATES ABBVIE BIOTHERAPEUTICS INC. 2025-02-27 — — US disclosed
US-7691967-B2 Smart pro-drugs of serine protease inhibitors TRUSTEES OF TUFTS COLLEGE (US) 2010-04-06 — — US disclosed
US-7691967-B2 Smart pro-drugs of serine protease inhibitors TRUSTEES OF TUFTS COLLEGE (US) 2010-04-06 — — US disclosed
US-5621133-A PREPARING A 1-(3,4-DIALKOXYPHENYL),3-HYDROXYALKANE(C6-C12) BY EPOXIDIZING A HALO DERIVATIVE WITH A BASE FOLLOWED BY DECYCLICIZING WITH AN ORGANOMETALLIC COMPOUND IN A SOLVENT; NAPHTHYLENES, ISOCHROMENES AND ISOTHIOCHROMENES DENINNO MICHAEL P (US) 1997-04-15 — — US disclosed
US-5591884-A PROTECTED HYDROXYALKYLCATECHOL INTERMEDIATES ABBOTT LABORATORIES (US) 1997-01-07 — — US disclosed
WO-1996038435-A1 DOPAMINE AGONISTS ABBOTT LABORATORIES (US) 1996-12-05 — — WO disclosed
EP-0474767-B1 DOPAMINE AGONISTS ABBOTT LAB (US) 1996-02-21 — — EP disclosed
EP-0474767-A4 DOPAMINE AGONISTS — 1992-07-08 — — EP disclosed
EP-0474767-A1 DOPAMINE AGONISTS. ABBOTT LAB (US) 1992-03-18 — — EP disclosed
WO-1990015056-A1 DOPAMINE AGONISTS ABBOTT LABORATORIES (US) 1990-12-13 — — WO disclosed
US-4277395-A OF ELASTASE; OLIGOPEPTIDES RICHARDSON-MERRELL INC. (US) 1981-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064961-A1 ANTI-CD19 ANTIBODY DRUG CONJUGATES CD22, CD79B, CD47 KMT2A 387/4885CTSK 2703/4885CTSS 3058/4885
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS CBLB, CBL, CBLC KMT2A 1486/4885CTSK 715/4885CTSS 874/4885
US-12478689-B2 Anti-CD19 antibody drug conjugates CD22, CD79B, CD47 KMT2A 387/4885CTSK 2703/4885CTSS 3058/4885
US-20250064962-A1 ANTI-CD19 ANTIBODY DRUG CONJUGATES CD22, CD79B, CD47 KMT2A 387/4885CTSK 2703/4885CTSS 3058/4885
US-12503452-B2 Antimicrobial compounds and methods MPO, NISCH, RPN2 KMT2A 4067/4885CTSK 151/4885CTSS 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.